Auro Laboratories Ltd (AUROLAB) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Auro Laboratories Ltd on NSE and BSE, with an AI summary of each filing.
Auro Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2026 ,inter alia, to consider and approve unaudited financial Results ....
Intimation · 13 Nov 2026, 5:30 am
Auro Laboratories Schedules Board Meeting for Q2 FY27 Financial Results Auro Laboratories Limited has scheduled a Board of Directors meeting on 13th Nov'26 to consider and approve the unaudited financial results, along with the Limited Review Report, for the quarter and half-year ended 30th Sep'26. In compliance with insider trading regulations, the trading window for designated persons and their immediate relatives will remain closed until 48 hours after the conclusion of the board meeting.
Auro Laboratories Limited has submitted the Unaudited Financial Results for the Quarter ended June 30, 2026.
Financial Result · 15 Aug 2026, 12:42 am
Auro Labs Q1FY27: Revenue Rises and Profitability Returns YoY Auro Laboratories reported strong YoY performance for Q1FY27 (quarter ended 30-Jun-26), reversing a prior-year loss. Revenue from operations surged 216% YoY to ₹876.81 lakhs. The company posted a Profit After Tax (PAT) of ₹104.56 lakhs, a significant turnaround from a loss of ₹10.55 lakhs in Q1FY26. Sequentially, revenue declined 10.8% QoQ, while PAT increased 7.7% QoQ. Basic EPS for the quarter stood at ₹1.68, compared to ₹1.56 in Q4FY26 and ₹(0.17) in Q1FY26.
Auro Laboratories Limited has submitted the Outcome of the Board Meeting held on August 14, 2026
Outcome · 15 Aug 2026, 12:33 am
Auro Laboratories Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lakh) ■ Revenue: 877 (+216.1% YoY | -10.8% QoQ) ■ EBITDA: 330 (+9974.1% YoY | -0.7% QoQ) ■ EBITDA Margin (%): 37.7 (+3650 bps YoY | +385 bps QoQ) ■ PAT: 105 (Loss to Profit YoY | +7.7% QoQ) ■ EPS (INR): 1.68 (Loss to Profit YoY | +7.7% QoQ)
Auro Laboratories Limited has submitted the Scrutinizer Report of 37th AGM held on August 11, 2026.
Annual General Meeting · 14 Aug 2026, 12:33 am
Auro Laboratories Limited has submitted the Proceedings/Outcome of the 37th Annual General Meeting held on August 11, 2026.
Annual General Meeting · 12 Aug 2026, 12:57 am
Auro Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Unaudited Financial Results ....
Intimation · 14 Aug 2026, 5:30 am
Auro Labs Board Meeting on Aug 14, 2026 to Approve Q1FY27 Results Auro Laboratories will hold a Board of Directors meeting on 14 Aug '26 to consider and approve its unaudited financial results for the quarter ended 30 Jun '26. The agenda also includes a Limited Review Report for the same period. In line with insider trading regulations, the trading window for designated persons, which closed on 26 Jun '26, will remain shut until 48 hours after the meeting's conclusion.
The Letter being send to the shareholders containing the web-link of the Annual Report of the Company for the FY 2025-2026 is enclosed.
Annual Report · 17 Jul 2026, 12:15 am
Enclosed Annual report of the Company for the FY 2025-2026
Others (Uncategorized) · 17 Jul 2026, 12:04 am
Enclosed Notice of 37th Annual General Meeting of the Company scheduled on August 11, 2026 at 11:30a.m. (IST)
Annual General Meeting · 16 Jul 2026, 11:52 pm
Auro Laboratories Limited hereby approve the re-appointment of Mr. Kiran Suresh Kulkarni as a Whole Time Director.
Change in Management · 01 Jul 2026, 12:38 am
Auro Labs Board Approves Re-appointment of Whole Time Director Auro Laboratories' Board of Directors, at its meeting on 30 Jun'26, approved the re-appointment of Mr. Kiran Suresh Kulkarni as Whole Time Director. The new three-year term is effective from 24 May'27 to 23 May'30, subject to shareholder approval at the upcoming Annual General Meeting (AGM). The 37th AGM is scheduled for 11 Aug'26 and will be held via video conferencing. Mr. Kulkarni has over 25 years of experience in API manufacturing QC/QA and manages functions at the company's manufacturing facility.
Auro Laboratories Limited scheduled the Board Meeting on June 30, 2026 to transact the business matter which are attached herewith.
Others (Uncategorized) · 01 Jul 2026, 12:23 am
Auro Labs Board Approves Re-appointment of Whole Time Director Auro Laboratories' Board approved the re-appointment of Mr. Kiran Suresh Kulkarni as Whole Time Director for a three-year term, effective from May 24, 2027, to May 23, 2030. This decision, made on Jun 30, 2026, is subject to shareholder approval at the upcoming 37th Annual General Meeting. The AGM is scheduled to be held via video conference on Aug 11, 2026. Mr. Kulkarni has over 25 years of experience in API manufacturing's QC/QA and general management functions.
Enclosed herewith appointment of Chief Financial Officer, Tax Auditor, Internal Auditor and Reappointment of Cost Auditor.
Change in Management · 30 May 2026, 2:23 am
Auro Labs Reports FY26 Results and Key Management Appointments Auro Laboratories reported a FY26 net profit of Rs. 353.29 lakhs, a 92% YoY increase. Q4 FY26 net profit was Rs. 97.07 lakhs, up from Rs. 39.42 lakhs YoY but down from Rs. 195.18 lakhs QoQ. FY26 revenue from operations grew 58% YoY to Rs. 3,073.98 lakhs. The board approved the audited financials on 29 May'26 and appointed Mr. Nitesh Bohra as the new CFO. It also appointed tax auditors and internal auditors, and re-appointed cost auditors for FY27.
Enclosed herewith Financial Results for the year ended March 31, 2026
Financial Result · 30 May 2026, 2:10 am
Auro Labs Reports Strong FY26 Results and Announces Key Appointments Auro Laboratories reported a PAT of ₹353.29 lakhs for FY26, up 92% YoY from ₹183.88 lakhs in FY25. Revenue from operations grew 58% YoY to ₹3,073.98 lakhs. For Q4 FY26, PAT was ₹97.07 lakhs, a 146% YoY increase, while revenue rose 33% YoY to ₹983.25 lakhs. The board approved audited financials and appointed Mr. Nitesh Bohra as the new CFO, effective 29 May'26. Several auditors were also appointed for FY27, with the statutory auditor issuing an unmodified opinion on the results.
Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we wish to inform you that the Board of Directors of the Company ....
Outcome · 30 May 2026, 1:58 am
Auro Labs Q4FY26 PAT Up 146%, Appoints New CFO Auro Laboratories reported strong Q4FY26 results with Net Profit surging 146% YoY to ₹97.07 lakhs and Revenue from Operations growing 32.9% YoY to ₹983.25 lakhs. For FY26, Net Profit rose 92.2% to ₹353.29 lakhs, while revenue increased 58.5% to ₹3,073.98 lakhs. The Board approved the audited financials on 29-May'26 and appointed Mr. Nitesh Bohra as the new CFO, effective immediately. Basic EPS for the quarter stood at ₹1.56, up from ₹0.63 YoY. An exceptional item of ₹14.42 lakhs was recorded.
Auro Laboratories Limited has submitted the Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 for Resignation of Mr. Kuntal Pancholi as the Chief Financial Officer & Key Managerial ....
Change in Management · 29 May 2026, 1:31 am
Auro Laboratories CFO Kuntal Pancholi Resigns Effective Immediately Auro Laboratories Limited announced the resignation of its Chief Financial Officer (CFO) and Key Managerial Personnel, Mr. Kuntal Pancholi, effective from the close of business on 28 May'26. The company filing confirmed the departure is immediate. Mr. Pancholi cited personal reasons for his resignation and confirmed there were no other material reasons for his departure. The company is now tasked with appointing a successor to the key finance role.
Auro Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve Audited Financial Results ....
Intimation · 29 May 2026, 5:30 am
Auro Labs Schedules Board Meeting for Q4 and FY26 Results Auro Laboratories Limited's Board of Directors will meet on May 29, 2026, to consider and approve the audited financial results for the quarter and year ended Mar 31, 2026. In line with SEBI regulations, the trading window for designated persons has been closed since Apr 01, 2026. The window will reopen 48 hours after the financial results are announced to the stock exchange.
Auro Laboratories Limited submits that the Company has received a "Certification of Substances Department" from the European Directorate for the Quality of Medicines & Healthcare ("EDQM") ....
Others (Uncategorized) · 06 May 2026, 12:45 am
Auro Labs Receives EDQM GMP Certification for Tarapur Facility Auro Laboratories announced on 5 May'26 its receipt of an "Attestation of Inspection" from the European Directorate for the Quality of Medicines & Healthcare (EDQM). The certification confirms that its manufacturing facility in MIDC Tarapur, Maharashtra, complies with EU Good Manufacturing Practice (GMP) requirements. This pertains to its CEP dossier for Metformin Hydrochloride, a key development for the company's access to European markets and regulatory standing. The specific inspection reference is INSP 2012-002-P05.
Auro Laboratories Limited submits that the Company has received a ''Certificate of GMP Compliance of a Manufacturer'' from Swissmedic Swiss Agency for Therapeutic Products for the Company''s ....
Others (Uncategorized) · 06 May 2026, 12:40 am
Auro Labs Receives Swissmedic GMP Certification for Tarapur Facility Auro Laboratories Limited announced on 05 May'26 that its manufacturing facility in M.I.D.C. Tarapur, Maharashtra, received a "Certificate of GMP Compliance of a Manufacturer" from Swissmedic. The certification (No. 26-0002), issued by the Swiss Agency for Therapeutic Products, confirms compliance with GMP requirements under the EU-Switzerland Mutual Recognition Agreement. This regulatory approval is a key development, potentially opening access to European markets for products manufactured at this site.
Auro Laboratories Limited has submitted the Disclosure in relation to Credit Rating obtained by the Company from Acuite Ratings & Research Limited.
Others (Uncategorized) · 14 Apr 2026, 11:46 pm
Auro Labs Assigned ACUITE BB+/Stable Rating on Bank Facilities Acuite Ratings assigned Auro Laboratories a 'BB+/Stable' long-term and 'A4+' short-term rating on its ₹79.80 crore bank facilities on 10th Apr'26. The rating reflects promoter experience but is constrained by a modest scale, intensive working capital, and a moderate financial risk profile post-capex. FY25 revenue fell to ₹19.40 crore from ₹53.64 crore in FY24 due to an expansion shutdown. Gearing rose to 1.05x from 0.63x. Post-capex manufacturing capacity increased to 2,100 MT from 1,260 MT, with full benefits yet to be realized.
Auro Laboratories Limited has submitted Financial Results for the quarter ended December 31, 2025.
Financial Result · 05 Feb 2026, 11:30 pm
Auro Laboratories Q3 FY26 Net Profit Soars Over 3,700% YoY Auro Laboratories reported a strong Q3 FY26, with net profit surging to ₹195.18 lakh from ₹5.10 lakh YoY. Revenue from operations for the quarter ended 31st Dec'25 grew 207% YoY to ₹939.30 lakh. On a QoQ basis, revenue increased by 6.3%, while net profit jumped by 172.7%. The Board of Directors approved these unaudited financial results on 5th Feb'26. The company’s Basic EPS stood at ₹3.13 for the quarter, a significant rise from ₹0.08 in the corresponding period last year.
Auro Laboratories Limited has submitted the Financial Results for the Quarter Ended December 31, 2025.
Outcome · 05 Feb 2026, 11:23 pm
Auro Laboratories Limited - Financial Result for the Quarter ended 31st Dec'25 (Standalone, INR Lakhs) ■ Revenue: 939 (+207.5% YoY | +6.3% QoQ) ■ EBITDA: 407 (+817.9% YoY | +72.5% QoQ) ■ EBITDA Margin (%): 43.3 (+2878 bps YoY | +1661 bps QoQ) ■ PAT: 195 (+3727.1% YoY | +172.7% QoQ) ■ EPS (INR): 3.13 (+3812.5% YoY | +172.2% QoQ)
Auro Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2026 ,inter alia, to consider and approve Unaudited Financial Results ....
Intimation · 05 Feb 2026, 5:30 am
Auro Laboratories Board Meeting on 05 Feb'26 to Approve Q3 FY26 Results Auro Laboratories Limited has scheduled a Board of Directors meeting on 05 Feb'26 to consider and approve the Unaudited Financial Results for the quarter ended 31 Dec'25. The trading window for designated persons, which closed on 26 Dec'25, will remain closed until 48 hours after the meeting's conclusion to prevent insider trading. The company will also discuss any other matters with the Chair's permission.
Auro Laboratories Limited wishes to inform that Company has received World Health Organization - Good Manufacturing Practices (WHO-GMP) Certifcate from Food & Drug Administration.
Others (Uncategorized) · 13 Nov 2025, 2:58 am
Auro Laboratories Limited has submitted unaudited Financial Results for the quarter and half year ended September 30, 2025
Financial Result · 13 Nov 2025, 12:41 am
Auro Laboratories Limited has submitted the Outcome of Board Meeting held on 12th November, 2025.
Outcome · 13 Nov 2025, 12:30 am